mycetoma
chronic
granulomat
subcutan
inflammatori
diseas
caus
certain
bacteria
actinomycetoma
fungi
eumycetoma
infect
progress
affect
deep
structur
bone
lead
massiv
destruct
deform
disabl
constitut
major
health
problem
mani
tropic
subtrop
countri
highli
endem
sudan
mexico
india
sudan
patient
manag
mycetoma
research
centr
khartoum
infect
fungu
mycetomati
diseas
affect
age
group
occur
commonli
young
men
age
group
year
diseas
usual
painless
clinic
diagnosi
commonli
base
presenc
subcutan
mass
multipl
sinus
seropurul
discharg
grain
treatment
opportun
compris
variou
chemotherapeut
agent
wide
surgic
excis
infect
tissu
may
possibl
end
limb
amput
although
individu
endem
area
antibodi
caus
agent
mycetoma
develop
diseas
innat
adapt
immun
play
role
host
resist
caus
agent
develop
diseas
therefor
tcell
respons
seem
import
progress
mycetoma
thelper
th
respons
report
primari
lesion
drain
lymph
node
patient
streptomyc
somaliensi
infect
stimul
peripher
blood
mononuclear
cell
mycetomati
antigen
whilst
respons
report
acut
phase
infect
healthi
endem
control
macrophag
stimul
live
conidia
pseudallescheria
boydii
also
induc
respons
wherea
hypha
induc
respons
experiment
infect
nude
athym
rat
mice
nocardia
n
asteroid
let
fatal
diseas
dissemin
addit
lymphocyt
previous
immunis
anim
directli
kill
n
asteroid
moreov
trevinovillarr
associ
report
n
brasiliensi
cell
wallassoci
lipid
implic
develop
experiment
actinomycetoma
act
princip
inhibit
sever
microbicid
effect
macrophag
includ
inhibit
product
phagocytosi
product
nitric
oxid
bacteri
kill
addit
demonstr
n
brasiliensi
wallassoci
lipid
suppress
express
major
histocompat
complex
class
ii
mhc
ii
dendrit
cell
dc
strongli
induc
product
cell
suggest
preexist
environ
caus
schistosomiasi
promot
develop
mycetoma
patient
mycetoma
significantli
posit
schistosoma
antibodi
healthi
endem
control
find
suggest
like
respons
antiinflammatoryimmunosuppress
cytokin
could
neg
impact
mycetoma
develop
diseas
progress
polypeptid
two
form
involv
acutephas
respons
account
sever
alter
relat
onset
variou
medic
disord
demonstr
recent
higher
level
cytokin
strongli
associ
surgic
treat
mycetoma
patient
comparison
treat
without
surgeri
known
proinflammatori
cytokin
involv
cell
death
coordin
cytokin
cleav
matur
activ
form
primarili
inflammasom
depend
caspas
activ
possibl
matur
secret
macrophag
activ
receptor
type
macrophag
fibroblast
epitheli
cell
induc
product
cxc
chemokin
bind
neutrophil
mediat
recruit
neutrophil
peripher
blood
stimul
inflamm
site
mycetoma
invas
therefor
higher
level
cytokin
advoc
crucial
role
mycetomati
pathogenesi
member
famili
emerg
potent
antiinflammatori
cytokin
suppress
innat
adapt
immun
respons
role
human
diseas
complet
understood
yet
howev
antiinflammatori
properti
associ
inflammatori
diseas
system
lupu
erythematosu
sle
inflammatori
bowel
diseas
report
neg
associ
proinflammatori
cytokin
peripher
blood
mononuclear
cell
pbmc
patient
degen
intervertebr
disc
grave
diseas
gd
protein
level
pbmc
dc
upregul
stimul
tolllik
receptor
tlr
ligand
proinflammatori
cytokin
vitro
express
macrophag
epitheli
cell
greatli
inhibit
product
major
proinflammatori
cytokin
macrophag
inflammatori
protein
vivo
transgen
protect
mice
lipopolysaccharidesinduc
shock
chemicalinduc
coliti
interfer
innat
protect
anticandida
host
respons
reduc
product
proinflammatori
cytokin
suppress
neutrophil
recruit
respons
candida
infect
result
increas
suscept
dissemin
candidiasi
moreov
markedli
reduc
inflammasom
activ
diseas
sever
murin
aspergillosi
addit
role
innat
immun
play
pivot
role
regul
adapt
immun
induc
regulatori
treg
cell
impair
activ
effector
tcell
respons
knowledg
studi
report
relationship
mycetoma
pathogenesi
far
frequent
denot
b
cell
cytokin
although
mainli
form
innat
immun
cell
compris
epitheli
cell
dc
macrophag
multim
play
fundament
role
immun
regul
extens
involv
infect
bind
heterodimer
receptor
princip
present
cell
natur
killer
nk
cell
induc
respons
consequ
increas
cytotox
cytokin
addit
cell
recent
identifi
heterodimer
cytokin
belong
cytokin
famili
compos
subunit
chain
epsteinbarrviru
ebv
induc
gene
chain
potent
immunosuppress
cytokin
produc
b
regulatori
cell
breg
dc
lesser
extent
endotheli
cell
smooth
muscl
cell
monocyt
biolog
effect
poorli
understood
howev
recognis
typic
antiinflammatori
cytokin
predomin
mechan
suppress
associ
abil
suppress
cell
prolifer
effector
function
given
direct
immunosuppress
effect
mani
studi
conduct
evalu
role
develop
sever
diseas
suppress
sever
type
chronic
inflammatori
diseas
inflammatori
bowel
diseas
decreas
sever
collagen
induc
arthriti
anim
via
enhanc
product
suppress
cell
asthma
model
intratrach
instil
decreas
diseas
sever
diminish
cell
count
reduc
product
bacteri
infect
shen
associ
found
mice
without
express
demonstr
obvious
improv
resist
infect
intracellular
bacteri
pathogen
salmonella
typhimurium
addit
increas
serum
adult
children
sepsi
administr
antibodi
diminish
dissemin
bacteria
septic
anim
similarli
tubercul
patient
exhibit
increas
serum
mrna
express
subunit
white
blood
cell
peripher
blood
mononuclear
cell
howev
role
mycetoma
pathogenesi
highlight
yet
background
studi
set
determin
cytokin
famili
cytokin
famili
circul
level
patient
infect
mycetomati
explor
associ
proinflammatoryantiinflammatori
cytokin
level
patient
demograph
characterist
correl
may
help
understand
pathogenesi
mycetoma
diseas
casecontrol
studi
conduct
mycetoma
research
centr
soba
univers
hospit
univers
khartoum
sudan
written
inform
consent
blood
sampl
taken
patient
match
control
popul
live
mycetoma
endem
area
sudan
sampl
collect
previous
describ
detail
nasr
associ
studi
individu
enrol
femal
male
overal
median
age
year
rang
year
seventi
patient
infect
mycetomati
studi
popul
divid
two
group
group
healthi
control
n
median
age
year
rang
year
group
ii
mycetoma
patient
n
patient
median
age
rang
year
group
similar
gender
distribut
male
group
diagnosi
eumycetoma
establish
variou
techniqu
includ
imag
molecular
histopatholog
techniqu
grain
cultur
surgic
biopsi
obtain
wide
local
incis
anaesthesia
appropri
surgic
condit
part
routin
patient
treatment
protocol
medic
examin
healthi
control
select
blood
bank
donor
healthi
volunt
match
patient
birthplac
geograph
healthi
control
question
acut
chronic
infecti
diseas
autoimmun
famili
histori
genet
disord
studi
particip
gave
inform
written
consent
studi
approv
ethic
committe
faculti
medicin
univers
khartoum
sudan
one
hundr
blood
collect
whatman
qualit
filter
paper
grade
circl
diam
mm
sigmaaldrich
chemic
co
st
loui
mo
usa
determin
cytokin
use
filter
paper
dri
whole
blood
spot
db
specimen
collect
prefer
facilit
collect
storag
transport
specimen
line
world
health
organ
recommend
also
use
sever
previou
studi
sera
extract
filterpap
sampl
describ
previous
detail
measur
sera
use
commerci
avail
enzym
link
immunosorb
assay
elisa
kit
abcam
cambridg
uk
serum
level
estim
use
sandwich
elisa
commerci
kit
color
gene
biolog
technolog
wuhan
china
cytokin
assay
perform
duplic
accord
manufactur
protocol
sensit
human
elisa
kit
cytokin
pgml
data
manag
spss
version
statist
softwar
window
ibm
spss
statist
appropri
statist
test
use
result
express
mean
standard
deviat
sd
median
interquartil
rang
iqr
spearman
correl
test
use
evalu
associ
serum
level
laboratori
valu
well
serum
cytokin
level
nonparametr
data
comparison
group
perform
use
test
oneway
anova
use
parametr
data
gener
linear
model
use
assess
risk
factor
circul
among
mycetoma
patient
differ
diseas
durat
lesion
size
mycetoma
infect
adjust
variabl
test
p
valu
consid
statist
signific
studi
approv
ethic
committe
soba
univers
hospit
khartoum
sudan
suh
written
inform
consent
taken
particip
enrol
studi
work
describ
perform
accord
declar
helsinki
level
cytokin
constitut
correl
among
mycetoma
patient
differ
lesion
diamet
level
constitut
posit
correl
lesion
diamet
tabl
hand
level
cytokin
constitut
neg
correl
tabl
furthermor
level
cytokin
constitut
posit
correl
tabl
howev
level
cytokin
constitut
neg
correl
tabl
patient
group
level
cytokin
constitut
correl
durat
mycetoma
infect
level
show
consist
posit
correl
neg
correl
tabl
wherea
level
constitut
posit
correl
tabl
howev
level
constitut
neg
correl
tabl
circul
serum
cytokin
level
determin
mycetoma
patient
compar
differ
lesion
diamet
among
mycetoma
patient
healthi
control
overal
signific
differ
level
studi
cytokin
four
group
three
level
lesion
diamet
healthi
control
tabl
distribut
level
decreas
dramat
lesion
diamet
lesion
diamet
cm
mean
sd
cm
cm
p
valu
howev
circul
serum
level
significantli
increas
lesion
diamet
lesion
diamet
cm
mean
sd
cm
cm
p
valu
tabl
result
show
signific
reduct
circul
level
versu
lesion
diamet
lesion
diamet
cm
mean
sd
cm
cm
p
valu
tabl
circul
level
significantli
increas
increas
lesion
diamet
lesion
diamet
cm
mean
sd
cm
cm
p
valu
tabl
circul
level
significantli
decreas
increas
diseas
durat
year
median
pgml
year
median
pgml
year
median
pgml
p
valu
tabl
serum
level
dramat
decreas
increas
diseas
durat
year
median
pgml
year
median
pgml
year
median
pgml
p
valu
tabl
howev
circul
level
posit
increas
differ
durat
mycetoma
infect
year
median
pgml
year
median
pgml
year
median
pgml
p
valu
tabl
similarli
serum
level
also
significantli
increas
increas
durat
mycetoma
infect
year
median
pgml
year
median
pgml
year
median
pgml
p
valu
tabl
analysi
risk
factor
higher
level
patient
mycetoma
show
signific
neg
associ
unit
increment
decreas
level
pgml
p
valu
tabl
serum
level
among
patient
lesion
diamet
cm
cm
significantli
lower
averag
respect
compar
patient
lesion
diamet
cm
refer
group
serum
level
among
patient
mycetoma
show
signific
differ
male
femal
p
valu
tabl
circul
level
significantli
decreas
increas
age
group
year
p
valu
year
p
valu
tabl
analysi
risk
factor
higher
serum
level
mycetoma
patient
show
signific
associ
p
valu
tabl
circul
level
among
patient
lesion
diamet
cm
cm
significantli
decreas
respect
compar
patient
lesion
diamet
cm
refer
group
p
valu
tabl
serum
level
among
mycetoma
patient
show
signific
differ
male
femal
p
valu
tabl
circul
level
show
signific
associ
differ
age
group
differ
type
antifung
medic
given
tabl
analysi
risk
factor
higher
circulatori
level
patient
mycetoma
show
neg
signific
associ
unit
increment
decreas
level
pgml
p
tabl
level
among
patient
diseas
durat
year
significantli
decreas
averag
pgml
compar
patient
diseas
durat
refer
group
howev
signific
differ
level
patient
infect
durat
year
year
p
valu
tabl
addit
serum
level
among
mycetoma
patient
show
signific
differ
male
femal
p
valu
tabl
furthermor
circul
level
significantli
decreas
increas
age
group
year
p
valu
year
p
valu
year
p
valu
tabl
interestingli
level
among
mycetoma
patient
show
statist
signific
differ
itraconazol
compar
ketoconazol
p
tabl
analysi
risk
factor
higher
level
patient
mycetoma
reveal
neg
signific
associ
unit
increment
decreas
level
pgml
p
valu
tabl
level
among
patient
mycetoma
diseas
durat
year
significantli
decreas
p
valu
averag
pgml
compar
patient
diseas
durat
refer
group
tabl
howev
patient
infect
durat
year
year
show
signific
differ
level
p
valu
furthermor
signific
differ
p
valu
level
male
femal
mycetoma
suffer
tabl
addit
circul
level
show
signific
associ
differ
age
group
tabl
interestingli
mycetoma
patient
treat
itraconazol
show
signific
increas
level
compar
patient
treat
ketoconazol
p
valu
tabl
although
mycetoma
repres
major
health
problem
mani
tropic
subtrop
area
prevent
control
measur
neglect
diseas
mycetoma
endem
area
individu
antibodi
caus
agent
howev
develop
diseas
research
believ
patient
develop
mycetoma
seem
defici
cellmedi
immun
henc
aim
investig
profil
proinflammatori
antiinflammatori
immunosuppress
cytokin
among
mycetoma
patient
associ
diseas
characterist
far
know
first
studi
address
relat
immunosuppress
cytokin
mycetoma
infect
data
show
eumycetoma
patient
present
higher
circul
level
compar
control
addit
serum
level
significantli
decreas
increas
lesion
diamet
diseas
durat
wherea
level
significantli
higher
increas
lesion
diamet
diseas
durat
find
indic
immunosuppress
cytokin
like
could
suppress
cellmedi
immun
respons
may
exacerb
diseas
progress
data
current
studi
clearli
show
serum
level
eumycetoma
patient
differ
lesion
size
diseas
durat
posit
correl
neg
correl
demonstr
first
line
innat
immun
respons
mycetoma
infect
phagocyt
macrophag
repres
major
phagocyt
cell
gener
protect
immun
fungal
infect
involv
activ
tlr
gener
inflammatori
cytokin
patternrecognit
receptor
pathogen
associ
molecular
pattern
proinflammatori
cytokin
produc
earli
respons
fungal
infect
promot
phagocytosi
mean
innat
immun
respons
follow
inflammatori
stimuli
sever
cell
type
includ
immun
nonimmun
cell
produc
protect
mechan
prevent
runaway
inflamm
excess
tissu
damag
directli
inhibit
gener
proinflammatori
cytokin
downregul
macrophag
cytokin
releas
therefor
innat
immun
moreov
induc
macrophag
toward
phenotyp
macrophag
critic
effector
cell
innat
immun
defens
system
characteris
high
express
level
ino
subsequ
product
secret
proinflammatori
cytokin
howev
macrophag
secret
antiinflammatori
cytokin
express
arginas
inhibit
product
thu
render
cell
ineffect
kill
infecti
agent
includ
fungal
agent
furthermor
dc
express
secret
higher
level
reduc
level
therefor
presenc
dc
impair
function
prime
cell
promot
abil
induc
treg
cell
produc
also
potent
antiinflammatori
cytokin
result
consist
shown
higher
circulatori
level
patient
mycetoma
neg
associ
unit
increment
decreas
level
pgml
base
aforement
data
specul
could
play
role
damp
inflammatori
respons
mycetoma
infect
lead
diseas
progress
patient
favor
current
work
circul
level
eumycetoma
patient
differ
lesion
size
diseas
durat
neg
correl
wherea
serum
level
increas
increas
lesion
size
diseas
durat
level
simultan
decreas
may
probabl
attempt
dampen
ongo
inflamm
pivot
role
inflammatori
cellmedi
immun
respons
macrophag
cytotox
tcell
ctl
constitut
main
compon
cellmedi
immun
play
import
role
protect
immun
mycetoma
infect
fatal
dissemin
n
asteroid
infect
occur
nude
athym
rat
mice
cell
previous
immun
anim
abl
kill
n
asteroid
new
infect
could
suppress
macrophag
respons
wherea
defici
increas
macrophag
activ
induc
respons
increas
immun
found
mice
lack
associ
higher
activ
macrophag
inflammatori
cell
well
enhanc
function
antigenpres
cell
anoth
infect
model
cao
cowork
report
higher
serum
level
septic
patient
compar
control
gradual
increas
increas
sepsi
sever
moreov
administr
antibodi
diminish
dissemin
bacteria
septic
anim
enhanc
local
neutrophil
recruit
increas
inflammatori
cytokin
chemokin
product
furthermor
suppress
prolifer
antigenspecif
ctl
product
data
reveal
higher
level
patient
mycetoma
neg
associ
unit
increment
decreas
level
pgml
find
indic
may
risk
factor
mycetoma
infect
neg
role
clinic
present
diseas
preval
mycetoma
infect
may
vari
age
data
studi
show
variat
mycetoma
preval
age
patient
age
year
find
consist
previou
studi
report
mycetoma
mostli
affect
age
yearsold
addit
data
demonstr
mycetoma
infect
predomin
male
male
femal
ratio
patient
group
find
run
parallel
result
previou
studi
demonstr
tertiari
facil
khartoum
sudan
male
femal
ratio
wherea
primari
care
level
white
nile
state
sudan
report
male
femal
ratio
anoth
studi
report
male
femal
ratio
mycetoma
infect
rang
predomin
mycetoma
male
may
attribut
increas
exposur
men
engag
differ
manual
labor
includ
agricultur
work
moreov
influenc
sex
hormon
might
role
suscept
mycetoma
infect
diseas
progress
data
show
patient
lesion
diamet
cm
result
reflect
mycetoma
patient
tend
present
late
massiv
lesion
find
could
attribut
natur
mycetoma
usual
painless
slowli
progress
addit
lack
health
facil
endem
area
low
socioeconom
statu
affect
patient
poor
health
educ
amongst
reason
current
treatment
mycetoma
suboptim
characteris
low
cure
rate
frequent
recurr
often
lead
amput
howev
clinic
experi
show
earli
small
mycetoma
lesion
associ
good
outcom
prevent
sever
complic
diseas
one
remark
find
current
studi
signific
increas
level
itraconazol
treatment
compar
ketoconazol
previou
studi
fricciu
colleagu
suggest
dose
itraconazol
lead
strong
inhibit
cytokin
slight
inhibit
cytokin
product
pbmc
hour
incub
result
demonstr
one
underlin
factor
associ
inhibit
cytokin
relat
itraconazol
conclus
studi
reveal
level
consist
posit
correl
differ
diamet
mycetoma
lesion
well
durat
howev
level
consist
neg
correl
differ
diamet
lesion
durat
mycetoma
infect
analysi
risk
factor
higher
circulatori
level
patient
mycetoma
show
neg
signific
associ
cytokin
unit
increment
decreas
level
pgml
level
among
patient
mycetoma
infect
durat
year
significantli
decreas
averag
pgml
compar
patient
mycetoma
infect
durat
refer
group
furthermor
risk
factor
higher
level
patient
mycetoma
reveal
neg
signific
associ
unit
increment
decreas
level
decreas
pgml
p
level
among
patient
mycetoma
infect
durat
year
significantli
decreas
p
valu
averag
pgml
compar
patient
mycetoma
infect
durat
refer
group
investig
need
explor
mechan
contribut
mycetoma
infect
outcom
help
understand
role
cytokin
pathogenesi
mycetoma
may
exploit
potenti
therapeut
target
prevent
mycetoma
diseas
recurr
